Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer.Preliminary results of a Vanderbilt trial

D. H. Johnson, J. D. Hainsworth, R. De Vore, K. R. Hande, F. A. Greco

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300, 350 or 400 mg/m2) and 21 days of oral etoposide (50 mg/m2/day). Thirty-three patients were evaluable for response (too early to assess the remaining patients) and 9 patients (27%) achieved a partial remission. Median survival was 29 weeks (range, 4+ to 71+ weeks). The primary toxicity was myelosuppression. Leukocyte and platelet count nadirs occurred between days 22 and 29. In cycle 1, median leukocyte nadir was 2.8 x 109/l and the platelet nadir was 142 x 109/l. Nonhematologic toxicities were modest and included alopecia in all patients, mild nausea, mild to moderate diarrhea, and an occasional increase in serum creatinine. Carboplatin plus oral etoposide is a tolerable outpatient regimen with modest activity against unresectable NSCLC.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalOncology
Volume49
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Carboplatin
Etoposide
Non-Small Cell Lung Carcinoma
Alopecia
Platelet Count
Leukocyte Count
Nausea
Diarrhea
Creatinine
Leukocytes
Outpatients
Blood Platelets
Survival
Serum

Keywords

  • Calboplatin
  • Etoposide
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer.Preliminary results of a Vanderbilt trial. / Johnson, D. H.; Hainsworth, J. D.; De Vore, R.; Hande, K. R.; Greco, F. A.

In: Oncology, Vol. 49, No. SUPPL. 1, 1992, p. 57-62.

Research output: Contribution to journalArticle

Johnson, D. H. ; Hainsworth, J. D. ; De Vore, R. ; Hande, K. R. ; Greco, F. A. / Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer.Preliminary results of a Vanderbilt trial. In: Oncology. 1992 ; Vol. 49, No. SUPPL. 1. pp. 57-62.
@article{c569509ee6da461da5f5fbdfabe0eda7,
title = "Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer.Preliminary results of a Vanderbilt trial",
abstract = "Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300, 350 or 400 mg/m2) and 21 days of oral etoposide (50 mg/m2/day). Thirty-three patients were evaluable for response (too early to assess the remaining patients) and 9 patients (27{\%}) achieved a partial remission. Median survival was 29 weeks (range, 4+ to 71+ weeks). The primary toxicity was myelosuppression. Leukocyte and platelet count nadirs occurred between days 22 and 29. In cycle 1, median leukocyte nadir was 2.8 x 109/l and the platelet nadir was 142 x 109/l. Nonhematologic toxicities were modest and included alopecia in all patients, mild nausea, mild to moderate diarrhea, and an occasional increase in serum creatinine. Carboplatin plus oral etoposide is a tolerable outpatient regimen with modest activity against unresectable NSCLC.",
keywords = "Calboplatin, Etoposide, Non-small cell lung cancer",
author = "Johnson, {D. H.} and Hainsworth, {J. D.} and {De Vore}, R. and Hande, {K. R.} and Greco, {F. A.}",
year = "1992",
language = "English (US)",
volume = "49",
pages = "57--62",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer.Preliminary results of a Vanderbilt trial

AU - Johnson, D. H.

AU - Hainsworth, J. D.

AU - De Vore, R.

AU - Hande, K. R.

AU - Greco, F. A.

PY - 1992

Y1 - 1992

N2 - Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300, 350 or 400 mg/m2) and 21 days of oral etoposide (50 mg/m2/day). Thirty-three patients were evaluable for response (too early to assess the remaining patients) and 9 patients (27%) achieved a partial remission. Median survival was 29 weeks (range, 4+ to 71+ weeks). The primary toxicity was myelosuppression. Leukocyte and platelet count nadirs occurred between days 22 and 29. In cycle 1, median leukocyte nadir was 2.8 x 109/l and the platelet nadir was 142 x 109/l. Nonhematologic toxicities were modest and included alopecia in all patients, mild nausea, mild to moderate diarrhea, and an occasional increase in serum creatinine. Carboplatin plus oral etoposide is a tolerable outpatient regimen with modest activity against unresectable NSCLC.

AB - Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300, 350 or 400 mg/m2) and 21 days of oral etoposide (50 mg/m2/day). Thirty-three patients were evaluable for response (too early to assess the remaining patients) and 9 patients (27%) achieved a partial remission. Median survival was 29 weeks (range, 4+ to 71+ weeks). The primary toxicity was myelosuppression. Leukocyte and platelet count nadirs occurred between days 22 and 29. In cycle 1, median leukocyte nadir was 2.8 x 109/l and the platelet nadir was 142 x 109/l. Nonhematologic toxicities were modest and included alopecia in all patients, mild nausea, mild to moderate diarrhea, and an occasional increase in serum creatinine. Carboplatin plus oral etoposide is a tolerable outpatient regimen with modest activity against unresectable NSCLC.

KW - Calboplatin

KW - Etoposide

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0026683687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026683687&partnerID=8YFLogxK

M3 - Article

C2 - 1323813

AN - SCOPUS:0026683687

VL - 49

SP - 57

EP - 62

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - SUPPL. 1

ER -